Standard BioTools director adds 220K+ potential shares via RSU and option grants

Rhea-AI Filing Summary

Form 4 filing for Standard BioTools Inc. (LAB) dated 24 June 2025 discloses equity compensation granted to board member Frank Witney on 20 June 2025.

Restricted Stock Units (RSUs): Witney received 94,592 RSUs at no cost. The award vests in full on the earlier of 20 June 2026 or one day prior to the company’s next annual shareholder meeting, contingent on continued service. Each RSU converts into one share of common stock upon vesting. After the grant, the director’s direct holdings rise to 210,862 shares; an additional 4,225 shares are held indirectly through a family trust.

Stock Option: He also received a non-qualified option for 125,660 shares with a strike price of $1.05. The option vests in twelve equal monthly installments starting 20 July 2025 and expires 20 June 2035. The filing reports no disposals and no cash paid for the RSUs; any cash impact would occur only if the option is exercised.

The transaction reflects a routine, service-based compensation grant rather than an open-market purchase, aligning director incentives with shareholder value but producing no immediate effect on cash flow or operations. If fully vested and exercised, the awards could increase the company’s outstanding share count by up to 220,252 shares, but the filing provides no data to assess relative dilution.

Insights

Securities Analyst

TL;DR: Routine director award: 94.6 k RSUs and 125.7 k options at $1.05; no cash impact, neutral for valuation.

The Form 4 shows Standard BioTools granted Frank Witney standard non-employee director equity on 20 June 2025. The 94,592 RSUs carry zero cost, vest in one year and immediately increase reported beneficial ownership to 210,862 shares. A separate option for 125,660 shares, struck at $1.05, vests monthly over one year and runs to 2035. No shares were sold, signalling no negative sentiment, but the transaction is not an open-market buy and thus offers limited incremental insight into insider conviction. Potential dilution from 220,252 new shares is modest absent context on total shares outstanding. Overall, the filing is routine and neutral in market impact.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Witney Frank

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy)	125,660	$0.00	--
Grant/Award	Common Stock	94,592	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to buy) — 125,660 shares (Direct); Common Stock — 210,862 shares (Direct); Common Stock — 4,225 shares (Indirect, See footnote)

Footnotes (1)

1. Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 20, 2026 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. Shares held indirectly by First Amended and Restated Revocable Trust Agreement for The Franklin R. Witney and Catherine J. Caulfield-Witney Trust Agreement Dated September 25, 2009 (dated July 31, 2018). The Option becomes exercisable in twelve equal monthly installments beginning on July 20, 2025, subject to the Reporting Person's continued service through the applicable vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Witney Frank

(Last) (First) (Middle)

C/O STANDARD BIOTOOLS INC.

2 TOWER PLACE, STE 2000

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/20/2025		A		94,592(1)	A	$0	210,862	D
Common Stock								4,225	I	See footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$1.05	06/20/2025		A		125,660		(3)	06/20/2035	Common Stock	125,660	$0	125,660	D

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 20, 2026 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.

2. Shares held indirectly by First Amended and Restated Revocable Trust Agreement for The Franklin R. Witney and Catherine J. Caulfield-Witney Trust Agreement Dated September 25, 2009 (dated July 31, 2018).

3. The Option becomes exercisable in twelve equal monthly installments beginning on July 20, 2025, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Frank Witney by Tomone Tanaka, Attorney-in-Fact	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many LAB shares did director Frank Witney acquire on 20 June 2025?

He received 94,592 restricted stock units, each representing one share upon vesting.

What is the strike price and size of the new LAB stock option granted to Frank Witney?

The option covers 125,660 shares at an exercise price of $1.05 per share.

When do the RSUs granted to Frank Witney vest?

They vest in full on 20 June 2026 or one day before the next annual meeting, whichever comes first.

How many LAB shares does Frank Witney now own after the transaction?

He beneficially owns 210,862 shares directly and 4,225 shares indirectly through a trust.

Does the filing reflect an open-market purchase or a routine equity award?

It reflects a routine compensation grant; no open-market purchases were reported.